Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005 May 15. 105(10):3768-85. [Medline].
Livingstone I, Ramamurthi S, Drummond S, Kemp E, Roberts F. Corneal perforation due to limbal involvement in Sézary syndrome. Graefes Arch Clin Exp Ophthalmol. 2011 Jul. 249(7):1091-4. [Medline].
Vonderheid EC, Bernengo MG, Burg G, et al. Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas. J Am Acad Dermatol. 2002 Jan. 46(1):95-106. [Medline].
Karube K, Aoki R, Nomura Y, et al. Usefulness of flow cytometry for differential diagnosis of precursor and peripheral T-cell and NK-cell lymphomas: analysis of 490 cases. Pathol Int. 2008 Feb. 58(2):89-97. [Medline].
Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007 Sep 15. 110(6):1713-22. [Medline].
Kaye FJ, Bunn PA Jr, Steinberg SM, et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med. 1989 Dec 28. 321(26):1784-90. [Medline].
Hoff NP, Groffik A, Mota R, et al. [Successful use of allogeneic stem cell transplantation for treatment-refractory mycosis fungoides]. Hautarzt. 2008 Oct. 59(10):779-82. [Medline].
Rook AH, Yoo EK, Grossman DJ, Kao DM, Fox FE, Niu Z. Use of biological response modifiers in the treatment of cutaneous T-cell lymphoma. Curr Opin Oncol. 1998 Mar. 10(2):170-4. [Medline].
Querfeld C, Rosen ST, Guitart J, Kuzel TM. The spectrum of cutaneous T-cell lymphomas: new insights into biology and therapy. Curr Opin Hematol. 2005 Jul. 12(4):273-8. [Medline].
Duvic M, Cather JC. Emerging new therapies for cutaneous T-cell lymphoma. Dermatol Clin. 2000 Jan. 18(1):147-56. [Medline].
Foss FM, Kuzel TM. Novel treatment approaches for cutaneous T-cell lymphoma. Cancer Treat Res. 1999. 99:227-40. [Medline].
Herrmann JJ, Roenigk HH Jr, Hönigsmann H. Ultraviolet radiation for treatment of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am. 1995 Oct. 9(5):1077-88. [Medline].
Zackheim HS. Cutaneous T cell lymphoma: update of treatment. Dermatology. 1999. 199(2):102-5. [Medline].
Sinha AA, Heald P. Advances in the management of cutaneous T-cell lymphoma. Dermatol Clin. 1998 Apr. 16(2):301-11. [Medline].
Gardner JM, Evans KG, Musiek A, Rook AH, Kim EJ. Update on treatment of cutaneous T-cell lymphoma. Curr Opin Oncol. 2009 Mar. 21(2):131-7. [Medline].
Prince HM, Whittaker S, Hoppe RT. How I treat mycosis fungoides and Sézary syndrome. Blood. 2009 Nov 12. 114(20):4337-53. [Medline].
Ramsay DL, Meller JA, Zackheim HS. Topical treatment of early cutaneous T-cell lymphoma. Hematol Oncol Clin North Am. 1995 Oct. 9(5):1031-56. [Medline].
Russell-Jones R. Extracorporeal photopheresis in cutaneous T-cell lymphoma. Inconsistent data underline the need for randomized studies. Br J Dermatol. 2000 Jan. 142(1):16-21. [Medline].
Fukushima T, Horio K, Matsuo E, et al. Successful cord blood transplantation for mycosis fungoides. Int J Hematol. 2008 Dec. 88(5):596-8. [Medline].
Olsen EA, Rook AH, Zic J, et al. Sézary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). J Am Acad Dermatol. 2011 Feb. 64(2):352-404. [Medline].
Diamandidou E, Cohen PR, Kurzrock R. Mycosis fungoides and Sezary syndrome. Blood. 1996 Oct 1. 88(7):2385-409. [Medline].
Koh HK, Charif M, Weinstock MA. Epidemiology and clinical manifestations of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am. 1995 Oct. 9(5):943-60. [Medline].
Carbone A, Bernardini L, Valenzano F, et al. Array-based comparative genomic hybridization in early-stage mycosis fungoides: recurrent deletion of tumor suppressor genes BCL7A, SMAC/DIABLO, and RHOF. Genes Chromosomes Cancer. 2008 Dec. 47(12):1067-75. [Medline].
van Doorn R, van Kester MS, Dijkman R, et al. Oncogenomic analysis of mycosis fungoides reveals major differences with Sezary syndrome. Blood. 2009 Jan 1. 113(1):127-36. [Medline].
Willemze R, Kerl H, Sterry W, et al. EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood. 1997 Jul 1. 90(1):354-71. [Medline].
Willemze R, Meijer CJ. EORTC classification for primary cutaneous lymphomas: a comparison with the R.E.A.L. Classification and the proposed WHO Classification. Ann Oncol. 2000. 11 Suppl 1:11-5. [Medline].
Kim YH, Willemze R, Pimpinelli N, Whittaker S, Olsen EA, Ranki A, et al. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007 Jul 15. 110(2):479-84. [Medline].
Hoque SR, Child FJ, Whittaker SJ, et al. Subcutaneous panniculitis-like T-cell lymphoma: a clinicopathological, immunophenotypic and molecular analysis of six patients. Br J Dermatol. 2003 Mar. 148(3):516-25. [Medline].
Massone C, Chott A, Metze D, Kerl K, Citarella L, Vale E, et al. Subcutaneous, blastic natural killer (NK), NK/T-cell, and other cytotoxic lymphomas of the skin: a morphologic, immunophenotypic, and molecular study of 50 patients. Am J Surg Pathol. 2004 Jun. 28(6):719-35. [Medline].
Burg G, Kempf W. Etiology and pathogenesis of cutaneous lymphomas. Burg G, Kempf W. Cutaneous Lymphomas. London: Taylor & Francis; 2005.
Burg G, Dummer R, Wilhelm M, et al. A subcutaneous delta-positive T-cell lymphoma that produces interferon gamma. N Engl J Med. 1991 Oct 10. 325(15):1078-81. [Medline].
Burg G, Kempf W, Cozzio A, et al. Cutaneous malignant lymphomas: update 2006. J Dtsch Dermatol Ges. 2006 Nov. 4(11):914-33. [Medline].
Jaffe ES, Krenacs L, Raffeld M. Classification of cytotoxic T-cell and natural killer cell lymphomas. Semin Hematol. 2003 Jul. 40(3):175-84. [Medline].
El Shabrawi-Caelen L, Cerroni L, Kerl H. The clinicopathologic spectrum of cytotoxic lymphomas of the skin. Semin Cutan Med Surg. 2000 Jun. 19(2):118-23. [Medline].
Miyamoto T, Yoshino T, Takehisa T, Hagari Y, Mihara M. Cutaneous presentation of nasal/nasal type T/NK cell lymphoma: clinicopathological findings of four cases. Br J Dermatol. 1998 Sep. 139(3):481-7. [Medline].
Kohler S. Extranodal NK/T-cell lymphoma, nasal type. LeBoit P, Burg G, Weedon D, Lyon SA. WHO Books: Tumors of the Skin. Geneva: World Health Organization IARC; X. 2006. 191-2.
Kim ST, Sim HJ, Jeon YS, Lee JW, Roh HJ, Choi SY, et al. Clinicopathological features and T-cell receptor gene rearrangement findings of mycosis fungoides in patients younger than age 20 years. J Dermatol. 2009 Jul. 36(7):392-402. [Medline].
Berti E, Tomasini D, Vermeer MH, Meijer CJ, Alessi E, Willemze R. Primary cutaneous CD8-positive epidermotropic cytotoxic T cell lymphomas. A distinct clinicopathological entity with an aggressive clinical behavior. Am J Pathol. 1999 Aug. 155(2):483-92. [Medline]. [Full Text].
Kempf W, Ostheeren-Michaelis S, Paulli M, et al. Granulomatous mycosis fungoides and granulomatous slack skin: a multicenter study of the Cutaneous Lymphoma Histopathology Task Force Group of the European Organization For Research and Treatment of Cancer (EORTC). Arch Dermatol. 2008 Dec. 144(12):1609-17. [Medline].
Girardi M, Heald PW, Wilson LD. The pathogenesis of mycosis fungoides. N Engl J Med. 2004 May 6. 350(19):1978-88. [Medline].
Criscione VD, Weinstock MA. Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002. Arch Dermatol. 2007 Jul. 143(7):854-9. [Medline].
Setoyama M, Katahira Y, Kanzaki T. Clinicopathologic analysis of 124 cases of adult T-cell leukemia/lymphoma with cutaneous manifestations: the smouldering type with skin manifestations has a poorer prognosis than previously thought. J Dermatol. 1999 Dec. 26(12):785-90. [Medline].
Alsaleh QA, Nanda A, Al-Ajmi H, Al-Sabah H, Elkashlan M, Al-Shemmari S, et al. Clinicoepidemiological features of mycosis fungoides in Kuwait, 1991-2006. Int J Dermatol. 2010 Dec. 49(12):1393-8. [Medline].
Agar NS, Wedgeworth E, Crichton S, et al. Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol. 2010 Nov 1. 28(31):4730-9. [Medline].
Tancrède-Bohin E, Ionescu MA, de La Salmonière P, et al. Prognostic value of blood eosinophilia in primary cutaneous T-cell lymphomas. Arch Dermatol. 2004 Sep. 140(9):1057-61. [Medline].
Weinstock MA, Gardstein B. Twenty-year trends in the reported incidence of mycosis fungoides and associated mortality. Am J Public Health. 1999 Aug. 89(8):1240-4. [Medline]. [Full Text].
Kim YH, Hoppe RT. Mycosis fungoides and the Sézary syndrome. Semin Oncol. 1999 Jun. 26(3):276-89. [Medline].
Fink-Puches R, Wolf P, Kerl H, Cerroni L. Lichen aureus: clinicopathologic features, natural history, and relationship to mycosis fungoides. Arch Dermatol. 2008 Sep. 144(9):1169-73. [Medline].
Scarisbrick JJ, Whittaker S, Evans AV, et al. Prognostic significance of tumor burden in the blood of patients with erythrodermic primary cutaneous T-cell lymphoma. Blood. 2001 Feb 1. 97(3):624-30. [Medline].
van Doorn R, Scheffer E, Willemze R. Follicular mycosis fungoides, a distinct disease entity with or without associated follicular mucinosis: a clinicopathologic and follow-up study of 51 patients. Arch Dermatol. 2002 Feb. 138(2):191-8. [Medline].
Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87). Br J Haematol. 1991 Nov. 79(3):428-37. [Medline].
Fink-Puches R, Zenahlik P, Bäck B, Smolle J, Kerl H, Cerroni L. Primary cutaneous lymphomas: applicability of current classification schemes (European Organization for Research and Treatment of Cancer, World Health Organization) based on clinicopathologic features observed in a large group of patients. Blood. 2002 Feb 1. 99(3):800-5. [Medline].
Bekkenk MW, Vermeer MH, Jansen PM, et al. Peripheral T-cell lymphomas unspecified presenting in the skin: analysis of prognostic factors in a group of 82 patients. Blood. 2003 Sep 15. 102(6):2213-9. [Medline].
Chan JK, Sin VC, Wong KF, Ng CS, Tsang WY, Chan CH, et al. Nonnasal lymphoma expressing the natural killer cell marker CD56: a clinicopathologic study of 49 cases of an uncommon aggressive neoplasm. Blood. 1997 Jun 15. 89(12):4501-13. [Medline].
Bekkenk MW, Jansen PM, Meijer CJ, Willemze R. CD56+ hematological neoplasms presenting in the skin: a retrospective analysis of 23 new cases and 130 cases from the literature. Ann Oncol. 2004 Jul. 15(7):1097-108. [Medline].
Mraz-Gernhard S, Natkunam Y, Hoppe RT, LeBoit P, Kohler S, Kim YH. Natural killer/natural killer-like T-cell lymphoma, CD56+, presenting in the skin: an increasingly recognized entity with an aggressive course. J Clin Oncol. 2001 Apr 15. 19(8):2179-88. [Medline].
Toro JR, Liewehr DJ, Pabby N, Sorbara L, Raffeld M, Steinberg SM, et al. Gamma-delta T-cell phenotype is associated with significantly decreased survival in cutaneous T-cell lymphoma. Blood. 2003 May 1. 101(9):3407-12. [Medline].
Quaglino P, Pimpinelli N, Berti E, et al. Time course, clinical pathways, and long-term hazards risk trends of disease progression in patients with classic mycosis fungoides: A multicenter, retrospective follow-up study from the Italian Group of Cutaneous Lymphomas. Cancer. 2012 Jun 6. [Medline].
Pope E, Weitzman S, Ngan B, et al. Mycosis fungoides in the pediatric population: report from an international Childhood Registry of Cutaneous Lymphoma. J Cutan Med Surg. 2010 Jan-Feb. 14(1):1-6. [Medline].
Shimauchi T, Sugita K, Nakamura M, Tokura Y. Leukaemic cutaneous T-cell lymphoma-manifesting papuloerythroderma with CD3(-) CD4(+) phenotype. Acta Derm Venereol. 2010. 90(1):68-72. [Medline].
Herrmann JL, Hughey LC. Recognizing large-cell transformation of mycosis fungoides. J Am Acad Dermatol. 2012 Jan 18. [Medline].
Roeschm A, Schleyer V, Landthaler M, Vogt T. Follicular mycosis fungoides: variability of a rare entity. Skinmed. 2005 Jan-Feb. 4(1):12-7. [Medline].
Muniesa C, Estrach T, Pujol RM, Gallardo F, Garcia-Muret P, Climent J, et al. Folliculotropic mycosis fungoides: clinicopathological features and outcome in a series of 20 cases. J Am Acad Dermatol. 2010 Mar. 62(3):418-26. [Medline].
Pileri A, Facchetti F, Rütten A, Zumiani G, Boi S, Fink-Puches R, et al. Syringotropic mycosis fungoides: a rare variant of the disease with peculiar clinicopathologic features. Am J Surg Pathol. 2011 Jan. 35(1):100-9. [Medline].
Bi MY, Curry JL, Christiano AM, Hordinsky MK, Norris DA, Price VH, et al. The spectrum of hair loss in patients with mycosis fungoides and Sézary syndrome. J Am Acad Dermatol. 2011 Jan. 64(1):53-63. [Medline].
Clarijs M, Poot F, Laka A, Pirard C, Bourlond A. Granulomatous slack skin: treatment with extensive surgery and review of the literature. Dermatology. 2003. 206(4):393-7. [Medline].
Marzano AV, Berti E, Paulli M, Caputo R. Cytophagic histiocytic panniculitis and subcutaneous panniculitis-like T-cell lymphoma: report of 7 cases. Arch Dermatol. 2000 Jul. 136(7):889-96. [Medline].
Török L, Gurbity TP, Kirschner A, Krenács L. Panniculitis-like T-cell lymphoma clinically manifested as alopecia. Br J Dermatol. 2002 Oct. 147(4):785-8. [Medline].
Santucci M, Pimpinelli N, Massi D, et al. Cytotoxic/natural killer cell cutaneous lymphomas. Report of EORTC Cutaneous Lymphoma Task Force Workshop. Cancer. 2003 Feb 1. 97(3):610-27. [Medline].
von den Driesch P, Coors EA. Localized cutaneous small to medium-sized pleomorphic T-cell lymphoma: a report of 3 cases stable for years. J Am Acad Dermatol. 2002 Apr. 46(4):531-5. [Medline].
Barrionuevo C, Anderson VM, Zevallos-Giampietri E, et al. Hydroa-like cutaneous T-cell lymphoma: a clinicopathologic and molecular genetic study of 16 pediatric cases from Peru. Appl Immunohistochem Mol Morphol. 2002 Mar. 10(1):7-14. [Medline].
Chen HH, Hsiao CH, Chiu HC. Hydroa vacciniforme-like primary cutaneous CD8-positive T-cell lymphoma. Br J Dermatol. 2002 Sep. 147(3):587-91. [Medline].
Gutte R, Kharkar V, Mahajan S, Chikhalkar S, Khopkar U. Granulomatous mycosis fungoides with hypohidrosis mimicking lepromatous leprosy. Indian J Dermatol Venereol Leprol. 2010 Nov-Dec. 76(6):686-90. [Medline].
Russell-Jones R. Diagnosing erythrodermic cutaneous T-cell lymphoma. Br J Dermatol. 2005 Jul. 153(1):1-5. [Medline].
Lange-Asschenfeldt S, Babilli J, Beyer M, Ríus-Diaz F, González S, Stockfleth E, et al. Consistency and distribution of reflectance confocal microscopy features for diagnosis of cutaneous T cell lymphoma. J Biomed Opt. 2012 Jan. 17(1):016001. [Medline].
Petrella T, Comeau MR, Maynadié M, et al. Agranular CD4+ CD56+ hematodermic neoplasm' (blastic NK-cell lymphoma) originates from a population of CD56+ precursor cells related to plasmacytoid monocytes. Am J Surg Pathol. 2002 Jul. 26(7):852-62. [Medline].
Smoller BR, Santucci M, Wood GS, Whittaker SJ. Histopathology and genetics of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am. 2003 Dec. 17(6):1277-311. [Medline].
Haghighi B, Smoller BR, LeBoit PE, Warnke RA, Sander CA, Kohler S. Pagetoid reticulosis (Woringer-Kolopp disease): an immunophenotypic, molecular, and clinicopathologic study. Mod Pathol. 2000 May. 13(5):502-10. [Medline].
Mao X, Lillington D, Scarisbrick JJ, et al. Molecular cytogenetic analysis of cutaneous T-cell lymphomas: identification of common genetic alterations in Sézary syndrome and mycosis fungoides. Br J Dermatol. 2002 Sep. 147(3):464-75. [Medline].
Pai RK, Mullins FM, Kim YH, Kong CS. Cytologic evaluation of lymphadenopathy associated with mycosis fungoides and Sezary syndrome: role of immunophenotypic and molecular ancillary studies. Cancer. 2008 Oct 25. 114(5):323-32. [Medline].
Burg G, Zwingers T, Staegemeir E, Santucci M. Interrater and intrarater variabilities in the evaluation of cutaneous lymphoproliferative T-cell infiltrates. EORTC-Cutaneous Lymphoma Project Group. Dermatol Clin. 1994 Apr. 12(2):311-4. [Medline].
Santucci M, Biggeri A, Feller AC, Massi D, Burg G. Efficacy of histologic criteria for diagnosing early mycosis fungoides: an EORTC cutaneous lymphoma study group investigation. European Organization for Research and Treatment of Cancer. Am J Surg Pathol. 2000 Jan. 24(1):40-50. [Medline].
Santucci M, Smoller B. ISCL study on early diagnosis of mycosis fungoides. (in preparation).
Pimpinelli N, Olsen EA, Santucci M, et al. Defining early mycosis fungoides. J Am Acad Dermatol. 2005 Dec. 53(6):1053-63. [Medline].
Furmanczyk PS, Wolgamot GM, Kussick SJ, Sabath DE, Olerud JE, Argenyi ZB. Diagnosis of mycosis fungoides with different algorithmic approaches. J Cutan Pathol. 2010 Jan. 37(1):8-14. [Medline].
Zelger B, Sepp N, Weyrer K, Grünewald K, Zelger B. Syringotropic cutaneous T-cell lymphoma: a variant of mycosis fungoides?. Br J Dermatol. 1994 Jun. 130(6):765-9. [Medline].
Gerami P, Guitart J. Basaloid folliculolymphoid hyperplasia: a distinctive finding in follicular mycosis fungoides. J Cutan Pathol. 2007 Dec. 34 Suppl 1:29-32. [Medline].
Imai S, Burg G, Braun-Falco O. Mycosis fungoides and Sézary's syndrome show distinct histomorphological features. Dermatologica. 1986. 173(3):131-5. [Medline].
Kamarashev J, Burg G, Kempf W, Hess Schmid M, Dummer R. Comparative analysis of histological and immunohistological features in mycosis fungoides and Sézary syndrome. J Cutan Pathol. 1998 Sep. 25(8):407-12. [Medline].
Sibaud V, Beylot-Barry M, Thiébaut R, et al. Bone marrow histopathologic and molecular staging in epidermotropic T-cell lymphomas. Am J Clin Pathol. 2003 Mar. 119(3):414-23. [Medline].
Takeshita M, Okamura S, Oshiro Y, et al. Clinicopathologic differences between 22 cases of CD56-negative and CD56-positive subcutaneous panniculitis-like lymphoma in Japan. Hum Pathol. 2004 Feb. 35(2):231-9. [Medline].
de Wolf-Peeters C, Achten R. gammadelta T-cell lymphomas: a homogeneous entity?. Histopathology. 2000 Apr. 36(4):294-305. [Medline].
Jones D, Vega F, Sarris AH, Medeiros LJ. CD4-CD8-"Double-negative" cutaneous T-cell lymphomas share common histologic features and an aggressive clinical course. Am J Surg Pathol. 2002 Feb. 26(2):225-31. [Medline].
Beljaards RC, Meijer CJ, Van der Putte SC, Hollema H, Geerts ML, Bezemer PD, et al. Primary cutaneous T-cell lymphoma: clinicopathological features and prognostic parameters of 35 cases other than mycosis fungoides and CD30-positive large cell lymphoma. J Pathol. 1994 Jan. 172(1):53-60. [Medline].
Natkunam Y, Smoller BR, Zehnder JL, Dorfman RF, Warnke RA. Aggressive cutaneous NK and NK-like T-cell lymphomas: clinicopathologic, immunohistochemical, and molecular analyses of 12 cases. Am J Surg Pathol. 1999 May. 23(5):571-81. [Medline].
Lambert WC, Cohen PJ, Schwartz RA. Surgical management of mycosis fungoides. J Med. 1997. 28(3-4):211-22. [Medline].
Thomas TO, Agrawal P, Guitart J, et al. Outcome of Patients Treated With a Single-Fraction Dose of Palliative Radiation for Cutaneous T-Cell Lymphoma. Int J Radiat Oncol Biol Phys. 2012 Jul 17. [Medline].
Tsuji H, Wada T, Murakami M, et al. Two cases of mycosis fungoides treated by reduced-intensity cord blood transplantation. J Dermatol. 2010 Dec. 37(12):1040-5. [Medline].
Wu PA, Kim YH, Lavori PW, Hoppe RT, Stockerl-Goldstein KE. A meta-analysis of patients receiving allogeneic or autologous hematopoietic stem cell transplant in mycosis fungoides and Sézary syndrome. Biol Blood Marrow Transplant. 2009 Aug. 15(8):982-90. [Medline].
D'Acunto C, Gurioli C, Neri I. Plaque stage mycosis fungoides treated with bexarotene at low dosage and UVB-NB. J Dermatolog Treat. 2010 Jan. 21(1):45-8. [Medline].
Chustecka Z. First proprietary gel product for cutaneous lymphoma. Medscape Medical News. August 27, 2013. Available at http://www.medscape.com/viewarticle/810067. Accessed: September 3, 2013.
Ceptaris receives FDA approval for Valchlor (mechlorethamine) gel for the treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma in patients who have received prior skin-directed therapy [press release]. Ceptaris Therapeutics Inc. Available at https://www.actelion.com/media/media-releases?newsId=1724720. 26 August 2013; Accessed: August 9, 2018.
Lessin SR, Duvic M, Guitart J, Pandya AG, Strober BE, Olsen EA, et al. Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. JAMA Dermatol. 2013 Jan. 149(1):25-32. [Medline]. [Full Text].
Horwitz SM, Kim YH, Foss F, et al. Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood. 2012 May 3. 119(18):4115-22. [Medline]. [Full Text].
Kim YH, Bagot M, Rook AH, Whittaker S, Duvic M. Anti-CCR4 monoclonal antibody, mogamulizumab (Moga), demonstrates superior efficacy compared to vorinostat (Vor) in patients with previously treated cutaneous T-cell lymphoma (CTCL): Results of the phase 3 MAVORIC study (abstract). J Invest Dermatol. 2018;138(5)suppl 1 (S78). Presented at the 2018 Annual Meeting of the International Investigative Dermatology, IID 2018, May 16-19, 2018. Orlando, FL.
Knobler E. Current management strategies for cutaneous T-cell lymphoma. Clin Dermatol. 2004 May-Jun. 22(3):197-208. [Medline].
Lundin J, Hagberg H, Repp R, et al. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood. 2003 Jun 1. 101(11):4267-72. [Medline].
Kanokrungsee S, Rajatanavin N, Rutnin S, Vachiramon V. Efficacy of narrowband ultraviolet B twice weekly for hypopigmented mycosis fungoides in Asians. Clin Exp Dermatol. 2012 Mar. 37(2):149-52. [Medline].
Ysebaert L, Truc G, Dalac S, et al. Ultimate results of radiation therapy for T1-T2 mycosis fungoides (including reirradiation). Int J Radiat Oncol Biol Phys. 2004 Mar 15. 58(4):1128-34. [Medline].
Onozuka T, Yokota K, Kawashima T, Shimada H, Kodama K, Kobayashi H, et al. An elderly patient with mycosis fungoides successfully treated with chronic low-dose oral etoposide therapy. Clin Exp Dermatol. 2004 Jan. 29(1):91-2. [Medline].
Dummer R, Urosevic M, Kempf W, Kazakov D, Burg G. Imiquimod induces complete clearance of a PUVA-resistant plaque in mycosis fungoides. Dermatology. 2003. 207(1):116-8. [Medline].
Apisarnthanarax N, Talpur R, Ward S, Ni X, Kim HW, Duvic M. Tazarotene 0.1% gel for refractory mycosis fungoides lesions: an open-label pilot study. J Am Acad Dermatol. 2004 Apr. 50(4):600-7. [Medline].
Singh F, Lebwohl MG. Cutaneous T-cell lymphoma treatment using bexarotene and PUVA: a case series. J Am Acad Dermatol. 2004 Oct. 51(4):570-3. [Medline].
Lee WS, Hwang JH, Kim MJ, Go SI, Lee A, Song HN, et al. Cyclosporine A as a Primary Treatment for Panniculitis-like T Cell Lymphoma: A Case with a Long-Term Remission. Cancer Res Treat. 2014 Jul. 46(3):312-6. [Medline].
Guenova E, Schanz S, Hoetzenecker W, Desimone JA, Mehra T, Voykov B, et al. Systemic corticosteroids for subcutaneous panniculitis-like T-cell lymphoma. Br J Dermatol. 2014 Apr 12. [Medline].
Ahern K, Gilmore ES, Poligone B. Pruritus in cutaneous T-cell lymphoma: A review. J Am Acad Dermatol. 2012 Jan 26. [Medline].
Jones GW, Hoppe RT, Glatstein E. Electron beam treatment for cutaneous T-cell lymphoma. Hematol Oncol Clin North Am. 1995 Oct. 9(5):1057-76. [Medline].
Leverkus M, Rose C, Bröcker EB, Goebeler M. Follicular cutaneous T-cell lymphoma: beneficial effect of isotretinoin for persisting cysts and comedones. Br J Dermatol. 2005 Jan. 152(1):193-4. [Medline].
Jacob R, Scala M, Fung MA. A case of syringotropic cutaneous T-cell lymphoma treated with local radiotherapy. J Am Acad Dermatol. 2009 Jan. 60(1):152-4. [Medline].
National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project. Cancer. 1982 May 15. 49 (10):2112-35. [Medline].
Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994 Sep 1. 84 (5):1361-92. [Medline]. [Full Text].
Swerdlow SH, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th Edition. Lyon, France: International Agency for Research on Cancer; 2008.
[Guideline] NCCN Clinical Practice Guidelines in Oncology. T-Cell lymphomas. National Comprehensive Cancer Network. Available at https://www.nccn.org/professionals/physician_gls/pdf/t-cell.pdf. Version 4.2018 — May 14, 2018; Accessed: August 9, 2018.
[Guideline] Trautinger F, Knobler R, Willemze R, Peris K, Stadler R, Laroche L, et al. EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome. Eur J Cancer. 2006 May. 42 (8):1014-30. [Medline]. [Full Text].
[Guideline] Willemze R, Hodak E, Zinzani PL, Specht L, Ladetto M, ESMO Guidelines Working Group. Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013 Oct. 24 Suppl 6:vi149-54. [Medline]. [Full Text].
[Guideline] Olsen EA, Whittaker S, Kim YH, et al. Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol. 2011 Jun 20. 29 (18):2598-607. [Medline]. [Full Text].
[Guideline] Kempf W, Pfaltz K, Vermeer MH, et al. EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood. 2011 Oct 13. 118 (15):4024-35. [Medline]. [Full Text].
Kim YH, Tavallaee M, Sundram U, Salva KA, Wood GS, Li S, et al. Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project. J Clin Oncol. 2015 Nov 10. 33 (32):3750-8. [Medline].
Wilcox RA. Cutaneous T-cell lymphoma: 2014 Update on diagnosis, risk-stratification, and management. Am J Hematol. 2014 Aug. 89(8):837-51. [Medline].
Pellegrini C, Stefoni V, Casadei B, Maglie R, Argnani L, Zinzani PL. Long-term outcome of patients with advanced-stage cutaneous T cell lymphoma treated with gemcitabine. Ann Hematol. 2014 Jun 8. [Medline].
Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, et al. Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses. J Hematol Oncol. 2014 Jan 23. 7(1):11. [Medline]. [Full Text].
Dummer R, Duvic M, Scarisbrick J, Olsen EA, Rozati S, Eggmann N, et al. Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous T-cell lymphomas (CTCL) (Mycosis fungoides and Sézary Syndrome). Ann Oncol. 2014 Jun 19. [Medline].